Atopic dermatitis drug risks

Executive Summary

The risks of atopic dermatitis drugs will be the topic of an Oct. 29-30 meeting of the Pediatric Subcommittee of FDA's Anti-Infective Drugs Advisory Committee. On Oct. 29, the committee will discuss the risks of hypothalamic-pituitary axis suppression in children being treated for atopic dermatitis. The committee will also hear reports on adverse events with Pfizer's Zyrtec and Accupril; Merck's Cozaar; AstraZeneca's Nolvadex, Orphan Medical's Busulfex and Bristol-Myers Squibb's Serzone. On Oct. 30, the committee will discuss long-term monitoring of cancer recurrence in atopic dermatitis patients who are being treated with immunosuppressants. The meeting will be held at the Hilton in Gaithersburg, Md. beginning at 8 a.m...